Restoring vessel physiology drives outcomes - The Bioadaptor experience

Join this #europcr 2024 session to delve into the unmet needs concerning drug-eluting stents (DES), including poor long-term clinical outcomes, with up to a 50% MACE rate at 10 years, and a non-plateauing 2-3% annual event rate. Explore how DynamX Bioadaptor technology addresses these challenges by maintaining the established flow lumen and restoring hemodynamic modulation of the artery. Discover the sustained clinical benefits demonstrated in a 2-year RCT, potentially establishing a new treatment standard for CAD patients. Gain insights into patient types benefiting most in clinical practice, such as those at higher risk of restenosis (e.g., LAD disease, long lesions, small vessels, co-morbidities), and younger patients with longer lifespans.
Sponsored by Elixir Medical
More videos on: www.pcronline.com/Cases-resou...
#des
#cad
#restenosis
#physiology